Subcutaneous bioavailability of a PRIMATIZED(TM) IgG1 anti-human CD4 monoclonal antibody is dose dependent in transgenic mice bearing human CD4

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 5, Issue 2, 1998, Pages 95-100

  Davis, Charles B ^a   Bugelski, Peter J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti CD4 mAb; Lymphatic Absorption; Sc Bioavailability; Transgenic Mice

Indexed keywords

CD4 ANTIGEN; CHIMERIC ANTIBODY; CROSS REACTING ANTIBODY; IMMUNOGLOBULIN G1; OKT 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; ASTHMA; CHO CELL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; KNOCKOUT MOUSE; LYMPH NODE; MALE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

EID: 0031810433     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.3109/10717549809031384     Document Type: Article

References (12)

1. Bocci, V. 1988. Immunology 64:1-9.
2. Bocci, V. 1991. Absorption of cytokines via oropharyngeal-associated lymphoid tissues. Clin. Pharmacokinet. 21:411-417.
3. Davies, B., and Morris, T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
4. Davis, C. B., Boyle, K. E., Urbanski, J. J., Paradysz, R. T., and Fong, K.-L. L. 1992. Disposition of metabolically labeled recombinant soluble CD4 (sT4) in male Sprague-Dawley rats following intravenous and subcutaneous administration. Drug Metab. Dispos. 20:695-705.
5. Davis, C. B., Garver, E. M., Kwok, D. C., and Urbanski, J. J. 1996. Disposition of metabolically radiolabeled CE9.1 - a macaque-human chimeric anti-human CD4 monoclonal antibody - in transgenic mice bearing human CD4. Drug Metab. Dispos. 24:1032-1037.
6. Hamilton, R. G., and Morrison, S. L. 1993. Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched deleted and point-mutated chimeric antibodies. J. Immunol. Meth. 158: 107-122.
7. Killeen, N., Sawada, S., and Littman, D. R. 1993. Regulated expression of human CD4 rescues helper cell development in mice lacking expression of endogenous CD4. EMBO J. 12:1547-1553.
8. Newman, R., Alberts, J., Anderson, D., Carner, K., Heard, C., Norton, F., Raab, R., Reff, M., Shuey, S., and Hanna, N. 1992. "Primatization" of recombinant antibodies for immunotherapy of human diseases: A macaque-human chimeric antibody against human CD4. Bio/Technology 10:1455-1460.
9. Rehm, S., Zimmerman, D. M., Truneh, A., and Bugelski, P. J. 1995. Immunohistochemical characterization of lymphocyte markers in HuCD4+ transgenic, MuCD4 knockout and MuCD4+ Balb/c mice. Abstract from the Society of Toxicologic Pathologists 14th International Symposium, San Diego, CA.
10. Supersaxo, A., Hein, W. R., and Steffen, H. 1990. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7:167-169.
11. Weinstein, J. N., Parker, R. J., Holton, O. D., Keenan, A. M., Covell, D. G., Black, C. D. V., and Sieber, S. M. 1985. Lymphatic delivery of monoclonal antibodies: Potential for detection and treatment of lymph node metastases. Cancer Invest. 3:85-95.
12. Weinstein, J. N., Steller, M. A., Keenan, A. M., Covell, D. G., Key, M. E., Sieber, S. M., Oldman, R. K., Hwang, K. M., and Parker, R. J. 1983. Monoclonal antibodies in the lymphatics: Selective delivery to lymph node metastases of a solid tumor. Science 222:423-426.